User login
Key clinical point: Ubrogepant shows similar efficacy and no new safety concerns for the treatment of perimenstrual migraine (pmM) and non-pmM attacks.
Major finding: At 2 hours post dose, pain freedom (P = .054) and pain relief (P = .683) were similar between pmM and non-pmM attacks treated with 50 mg ubrogepant. Absence of migraine-associated symptoms (photophobia and phonophobia) and functional disability was not significantly different between pmM and non-pmM attacks treated with 50 mg ubrogepant, with similar findings observed for 100 mg ubrogepant. Nausea and dizziness were reported in < 6% of participants overall in both the 50 mg and 100 mg ubrogepant groups.
Study details: This post hoc analysis of a long-term safety extension trial included 734 women with migraine, of whom 278 and 716 were treated with ubrogepant (50 mg or 100 mg) for ≥ 1 pmM and non-pmM attacks, respectively.
Disclosures: This study was funded by Allergan (prior to its acquisition by AbbVie). Four authors declared being employees of or holding stocks in AbbVie, and the other authors declared ties with various sources, including AbbVie.
Source: MacGregor EA et al. Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis. Headache. 2023 (Sep 1). doi: 10.1111/head.14619
Key clinical point: Ubrogepant shows similar efficacy and no new safety concerns for the treatment of perimenstrual migraine (pmM) and non-pmM attacks.
Major finding: At 2 hours post dose, pain freedom (P = .054) and pain relief (P = .683) were similar between pmM and non-pmM attacks treated with 50 mg ubrogepant. Absence of migraine-associated symptoms (photophobia and phonophobia) and functional disability was not significantly different between pmM and non-pmM attacks treated with 50 mg ubrogepant, with similar findings observed for 100 mg ubrogepant. Nausea and dizziness were reported in < 6% of participants overall in both the 50 mg and 100 mg ubrogepant groups.
Study details: This post hoc analysis of a long-term safety extension trial included 734 women with migraine, of whom 278 and 716 were treated with ubrogepant (50 mg or 100 mg) for ≥ 1 pmM and non-pmM attacks, respectively.
Disclosures: This study was funded by Allergan (prior to its acquisition by AbbVie). Four authors declared being employees of or holding stocks in AbbVie, and the other authors declared ties with various sources, including AbbVie.
Source: MacGregor EA et al. Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis. Headache. 2023 (Sep 1). doi: 10.1111/head.14619
Key clinical point: Ubrogepant shows similar efficacy and no new safety concerns for the treatment of perimenstrual migraine (pmM) and non-pmM attacks.
Major finding: At 2 hours post dose, pain freedom (P = .054) and pain relief (P = .683) were similar between pmM and non-pmM attacks treated with 50 mg ubrogepant. Absence of migraine-associated symptoms (photophobia and phonophobia) and functional disability was not significantly different between pmM and non-pmM attacks treated with 50 mg ubrogepant, with similar findings observed for 100 mg ubrogepant. Nausea and dizziness were reported in < 6% of participants overall in both the 50 mg and 100 mg ubrogepant groups.
Study details: This post hoc analysis of a long-term safety extension trial included 734 women with migraine, of whom 278 and 716 were treated with ubrogepant (50 mg or 100 mg) for ≥ 1 pmM and non-pmM attacks, respectively.
Disclosures: This study was funded by Allergan (prior to its acquisition by AbbVie). Four authors declared being employees of or holding stocks in AbbVie, and the other authors declared ties with various sources, including AbbVie.
Source: MacGregor EA et al. Safety and efficacy of ubrogepant for the acute treatment of perimenstrual migraine attacks: A post hoc analysis. Headache. 2023 (Sep 1). doi: 10.1111/head.14619